| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685443 | PFIZER | Sequestering subunit and related compositions and methods |
Jul, 2025
(1 year, 9 months from now) | |
| US7815934 | PFIZER | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) | |
Troxyca Er is owned by Pfizer.
Troxyca Er contains Naltrexone Hydrochloride; Oxycodone Hydrochloride.
Troxyca Er has a total of 2 drug patents out of which 0 drug patents have expired.
Troxyca Er was authorised for market use on 19 August, 2016.
Troxyca Er is available in capsule, extended release;oral dosage forms.
Troxyca Er can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.
The generics of Troxyca Er are possible to be released after 12 December, 2027.
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
TROXYCA ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic